الفهرس 
Table of Contents
HCV and Living donor liver transplantationOnly 14 pages are availabe for public view
 |  | from | 156 |  |  |
| | | from | 156 | | |
Abstract
Immunosuppressive therapy is the cornerstone in liver transplantation with an obvious impact both on the short and long term outcomes of the patients. This impact depends on multiple factors ; recipient factors, donor graft, operative efficiency, and the most important of which is the experience of the transplant physician. Immunosuppressive therapy in liver transplantation should be tailored on an individual basis and prescribed only by an experienced physician in liver transplantation (transplant hepatologist). We recommend the use of Evr early in the setting of live donor liver transplantion for HCV etiology ± HCC and specifically in the presence of pretransplant or early post transplant renal dysfunction provided that the following criteria are fulfilled.